Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.58 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 5/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6997742 | 0.81 | RAB9A (0.49) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1568235 | 0.74 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL11040166 | 0.73 | RAB9A (0.66) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL17673049 | 0.73 | RAB9A (0.97) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4354272 | 0.71 | RAB9A (0.88) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2129716 | 0.71 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4662136 | 0.71 | RAB9A (0.83) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL30969954 | 0.71 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL7698230 | 0.70 | KMT2A (0.68) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3818841 | 0.70 | RAB9A (0.83) | RAB9ANPC1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1037633-B1 | ANTIVIRAL COMPOUNDS | IAF BIOCHEM INT (CA) | 2003-09-10 | — | — | EP | claimed |
| US-20010031765-A1 | Antiviral compounds | BIOCHEM PHARMA INC. | 2001-10-18 | — | — | US | claimed |
| US-6255318-B1 | CYTOMEGLO VIRUS | BIOCHEM PHARMA INC. (CA) | 2001-07-03 | — | — | US | claimed |
| CN-1283995-A | Antiviral compounds | IAF BIOCHEM INT (CA) | 2001-02-14 | — | — | CN | claimed |
| EP-1037633-A1 | ANTIVIRAL COMPOUNDS | BIOCHEM PHARMA INC (CA) | 2000-09-27 | — | — | EP | claimed |
| WO-1999029318-A1 | ANTIVIRAL COMPOUNDS | BIOCHEM PHARMA INC. (CA) | 1999-06-17 | — | — | WO | claimed |
| EP-1037633-B1 | ANTIVIRAL COMPOUNDS | IAF BIOCHEM INT (CA) | 2003-09-10 | — | — | EP | disclosed |
| US-6534520-B2 | Antiviral compounds | BIOCHEM PHARMA INC. (CA) | 2003-03-18 | — | — | US | disclosed |
| US-20010031765-A1 | Antiviral compounds | BIOCHEM PHARMA INC. | 2001-10-18 | — | — | US | disclosed |
| US-6255318-B1 | CYTOMEGLO VIRUS | BIOCHEM PHARMA INC. (CA) | 2001-07-03 | — | — | US | disclosed |
| CN-1283995-A | Antiviral compounds | IAF BIOCHEM INT (CA) | 2001-02-14 | — | — | CN | disclosed |
| EP-1037633-A1 | ANTIVIRAL COMPOUNDS | BIOCHEM PHARMA INC (CA) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999029318-A1 | ANTIVIRAL COMPOUNDS | BIOCHEM PHARMA INC. (CA) | 1999-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031765-A1 | Antiviral compounds | ZC3HAV1, IFNAR1, EIF2AK2 | RAB9A 926/4885NPC1 1407/4885SMN1; SMN2 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.